Publications

PETRA

  • Ferrández, M.C., Golla, S.S.V., Eertink, J.J. de Vries B. M., Wiegers S. E., Zwezerijnen G. J. C., Pieplenbosch S., Schilder L., Heymans M. W., Zijlstra J. M., Boellaard R. Sensitivity of an AI method for [18F]FDG PET/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols. EJNMMI Res 13, 88 (2023). https://doi.org/10.1186/s13550-023-01036-8

  • Ferrández, M.C., Golla, S.S.V., Eertink, J.J. de Vries B. M., Lugtenburg P. J., Wiegers S.E., Zwerzerijnen G. J. C., Pieplenbosch S., Kurch L., Huttmann A., Hanoun C., Duhrsen U., de Vet H. C. W. Zijlstra J., Boellaard R. An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients. Sci Rep 13, 13111 (2023). https://doi.org/10.1038/s41598-023-40218-1

  • Eertink, J. J., Zwezerijnen, G. J. C., Heymans, M. W., Pieplenbosch, S., Wiegers, S. E., Dührsen, U., Hüttmann, A., Kurch, L., Hanoun, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Czibor, S., Györke, T., Chamuleau, M. E. D., Hoekstra, O. S., de Vet, H. C. W., Boellaard, R., Zijlstra, J. M. (2023). Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood141(25), 3055–3064. https://doi.org/10.1182/blood.2022018558

  • Zwezerijnen, G.J.C., Eertink, J.J., Ferrández, M.C.  Sanne E. Wiegers, Coreline N. Burggraaff, Pieternella J. Lugtenburg, Martijn W. Heymans, Henrica C. W. de Vet, Josée M. Zijlstra, Ronald Boellaard. Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor. Eur J Nucl Med Mol Imaging 50, 486–493 (2023). https://doi.org/10.1007/s00259-022-05977-5

  • Ferrández, M.C., Eertink, J.J., Golla, S.S.V. Wiegers S. E., Zwezerijnen G. J. C., Pieplenbosch S., Zijlstra J. M., Boellaard R. Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods. EJNMMI Res 12, 44 (2022). https://doi.org/10.1186/s13550-022-00916-9

  • Eertink JJ, Zwezerijnen GJC, Wiegers SE, et al. (2023). Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. Blood Adv. 2023;7(2):214-223. doi:10.1182/bloodadvances.2022008629

  • Eertink JJ, Zwezerijnen GJC, Cysouw MCF, et al. (2022). Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features. Eur J Nucl Med Mol Imaging. 2022;49(13):4642-4651. doi:10.1007/s00259-022-05916-4

  • Eertink JJ, Heymans MW, Zwezerijnen GJC, et al. (2022). External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients. EJNMMI Res. 2022;12(1):58. https://doi:10.1186/s13550-022-00931-w

  • Mikhaeel, N. G., Heymans, M. W., Eertink, J. J., de Vet, H., Boellaard, R., Dührsen, U., Ceriani, L., Schmitz, C., Wiegers, S. E., Hüttmann, A., Lugtenburg, P. J., Zucca, E., Zwezerijnen, G., Hoekstra, O. S., Zijlstra, J. M., & Barrington, S. F. (2022). Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, JCO2102063. https://doi.org/10.1200/JCO.21.02063

  • Eertink, J.J., van de Brug, T., Wiegers, S.E. et al. (2022) 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 49, 932–942. https://doi.org/10.1007/s00259-021-05480-3

  • Barrington, S. F., Eertink, J. J., de Vet, H., George Mikhaeel, N., Hoekstra, O. S., & Zijlstra, J. M. (2021). Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine62(11), 1655–1656. https://doi.org/10.2967/jnumed.121.262317

  • Eertink JJ, Burggraaff CN, Heymans MW, et al. (2021) Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv. 2021;5:2375-2384 https://doi.org/10.1182/bloodadvances.2021004467

  • Zwezerijnen GJ, Eertink JJ, Burggraaff CN, et al. (2021) Interobserver agreement in automated metabolic tumor volume measurements of Deauville score 4 and 5 lesions at interim (18)F-FDG PET in DLBCL. J Nucl Med. 2021 https://doi.org/10.2967/jnumed.120.258673

  • Barrington SF, Zwezerijnen B, de Vet HCW, et al. (2021) Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. J Nucl Med. 2021;62:332-337 https://doi.org/10.2967/jnumed.119.238923

  • Burggraaff CN, Rahman F, Kassner I, et al. (2020) Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. Mol Imaging Biol. 2020;22:1102-1110 https://doi.org/10.1007/s11307-020-01474-z

  • Burggraaff CN, de Jong A, Hoekstra OS, et al. (2019) Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:65-79 https://doi.org/10.1007/s00259-018-4103-3

  • Burggraaff CN, Cornelisse AC, Hoekstra OS, et al. (2018) Interobserver Agreement of Interim and End-of-Treatment (18)F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. J Nucl Med. 2018;59:1831-1836. https://doi.org/10.2967/jnumed.118.210807

  • Ferrández, M.C., Golla, S.S.V., Eertink, J.J. de Vries B. M., Wiegers S. E., Zwezerijnen G. J. C., Pieplenbosch S., Schilder L., Heymans M. W., Zijlstra J. M., Boellaard R. Sensitivity of an AI method for [18F]FDG PET/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols. EJNMMI Res 13, 88 (2023). https://doi.org/10.1186/s13550-023-01036-8

Consortium Members

  • Genta, S., Ghilardi, G., Cascione, L., Juskevicius, D., Tzankov, A., Schär, S., Milan, L., Pirosa, M. C., Esposito, F., Ruberto, T., Giovanella, L., Hayoz, S., Mamot, C., Dirnhofer, S., Zucca, E., & Ceriani, L. (2022). Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers14(4), 1018. https://doi.org/10.3390/cancers14041018

  • Ceriani, L., Milan, L., Cascione, L., Gritti, G., Dalmasso, F., Esposito, F., Pirosa, M. C., Schär, S., Bruno, A., Dirnhofer, S., Giovanella, L., Hayoz, S., Mamot, C., Rambaldi, A., Chauvie, S., & Zucca, E. (2022). Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. Hematological oncology40(1), 11–21. https://doi.org/10.1002/hon.2935

  • Rekowski, J., Hüttmann, A., Schmitz, C.,  Müller, S.Kurch, L., Kotzerke, J., Franzius, C., Weckesser, M., Bengel, F., Freesmeyer, M.Hertel, A.,  Krohn T., Holzinger, J., Brink, I., Haberkorn, U., Nyuyki, F., van Assema, D.Geworski, L., Hasenclever, D.,  Jöckel K. & Dührsen, U. (2021). Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method,

  • Kurch, L., Hüttmann, A., Georgi, T. W., Rekowski, J., Sabri, O., Schmitz, C., Kluge, R., Dührsen, U., & Hasenclever, D. (2021). Interim PET in Diffuse Large B-Cell Lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine62(8), 1068–1074. https://doi.org/10.2967/jnumed.120.255034

  • Kurch, L., Dührsen, U., Hüttmann, A., Georgi, T. W., Sabri, O., Kluge, R., & Hasenclever, D. (2021). Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma. EJNMMI research11(1), 90. https://doi.org/10.1186/s13550-021-00827-1

  • Broecker-Preuss, M., Becher-Boveleth, N., Müller, S. P., Hüttmann, A., Hanoun, C., Grafe, H., Richter, J., Klapper, W., Rekowski, J., Bockisch, A., & Dührsen, U. (2021). Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. Journal of cancer research and clinical oncology, 10.1007/s00432-021-03796-z. Advance online publication. https://doi.org/10.1007/s00432-021-03796-z

  • Zucca, E., Cascione, L., Ruberto, T., Facchinelli, D., Schär, S., Hayoz, S., Dirnhofer, S., Giovanella, L., Bargetzi, M., Mamot, C., & Ceriani, L. (2020). Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. Hematological oncology38(5), 715–725. https://doi.org/10.1002/hon.2805

  • Luca Ceriani, Giuseppe Gritti, Luciano Cascione, Maria Cristina Pirosa, Angela Polino, Teresa Ruberto, Anastasios Stathis, Andrea Bruno, Alden A. Moccia, Luca Giovanella, Stefanie Hayoz, Sämi Schär, Stefan Dirnhofer, Alessandro Rambaldi, Giovanni Martinelli, Christoph Mamot, Emanuele Zucca; SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv 2020; 4 (6): 1082–1092. doi: https://doi.org/10.1182/bloodadvances.2019001201

  • Wagner, B., Dührsen, U., Hüttmann, A., Nückel, H., Michita, R. T., Rohn, H., Schramm, S., Horn, P. A., & Rebmann, V. (2020). Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma. Cancers12(11), 3429. https://doi.org/10.3390/cancers12113429

  • Schmitz, C., Rekowski, J., Reinke, S., Müller, S. P., Hüttmann, A., Klapper, W., & Dührsen, U. (2020). Metabolic tumor volume, cancer cell fraction, and prognosis – the case of T-cell/histiocyte-rich large B-cell lymphoma. Leukemia & lymphoma61(6), 1372–1379. https://doi.org/10.1080/10428194.2020.1713319

  • Schmitz, C., Rekowski, J., Müller, S. P., Hertenstein, B., Franzius, C., Ganser, A., Bengel, F. M., Kroschinsky, F., Kotzerke, J., La Rosée, P., Freesmeyer, M., Hoeffkes, H. G., Hertel, A., Behringer, D., Mesters, R., Weckesser, M., Mahlmann, S., Haberkorn, U., Martens, U., … Hüttmann, A. (2020). Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. Hematological Oncology38(3), 244-256. https://doi.org/10.1002/hon.2697

  • Schmitz, C., Rekowski, J., Müller, S. P., Farsijani, N., Hertenstein, B., Franzius, C., von Verschuer, U., La Rosée, P., Freesmeyer, M., Wilop, S., Krohn, T., Raghavachar, A., Ganser, A., Bengel, F. M., Prange-Krex, G., Kroschinsky, F., Kotzerke, J., Giagounidis, A., Dührsen, U., & Hüttmann, A. (2020). Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. Cancer medicine9(22), 8386–8396. https://doi.org/10.1002/cam4.3448

  • Schmitz, C., Hüttmann, A., Müller, S. P., Hanoun, M., Boellaard, R., Brinkmann, M., Jöckel, K. H., Dührsen, U., & Rekowski, J. (2020). Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. European journal of cancer (Oxford, England : 1990)124, 25–36. https://doi.org/10.1016/j.ejca.2019.09.027

  • Schmitz, C., Hüttmann, A., Müller, S. P., Hanoun, M., Boellaard, R., Brinkmann, M., Jöckel, K. H., Dührsen, U., & Rekowski, J. (2020). Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25-36]. European journal of cancer (Oxford, England : 1990)136, 207–208. https://doi.org/10.1016/j.ejca.2020.05.019

  • Schmitz, C., Hüttmann, A., Müller, S. P., Hanoun, M., Boellaard, R., Brinkmann, M., Jöckel, K. H., Dührsen, U., & Rekowski, J. (2019). Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination. Data in brief28, 104976. https://doi.org/10.1016/j.dib.2019.104976

  • Richter, J., Hüttmann, A., Rekowski, J., Schmitz, C., Gärtner, S., Rosenwald, A., Hansmann, M. L., Hartmann, S., Möller, P., Wacker, H. H., Feller, A., Thorns, C., Müller, S., Dührsen, U., & Klapper, W. (2019). Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. Blood cancer journal9(9), 67. https://doi.org/10.1038/s41408-019-0230-8

  • Hüttmann, A., Rekowski, J., Müller, S. P., Hertenstein, B., Franzius, C., Mesters, R., Weckesser, M., Kroschinsky, F., Kotzerke, J., Ganser, A., Bengel, F. M., La Rosée, P., Freesmeyer, M., Höffkes, H. G., Hertel, A., Behringer, D., Prange-Krex, G., Griesshammer, M., Holzinger, J., Wilop, S., … Dührsen, U. (2019). Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial. Annals of hematology98(4), 897–907. https://doi.org/10.1007/s00277-018-3578-0

  • Dührsen, U., Müller, S., Hertenstein, B., Thomssen, H., Kotzerke, J., Mesters, R., Berdel, W. E., Franzius, C., Kroschinsky, F., Weckesser, M., Kofahl-Krause, D., Bengel, F. M., Dürig, J., Matschke, J., Schmitz, C., Pöppel, T., Ose, C., Brinkmann, M., La Rosée, P., Freesmeyer, M., … PETAL Trial Investigators (2018). Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology36(20), 2024–2034. https://doi.org/10.1200/JCO.2017.76.8093

  • Mamot, C., Klingbiel, D., Hitz, F., Renner, C., Pabst, T., Driessen, C., Mey, U., Pless, M., Bargetzi, M., Krasniqi, F., Gigli, F., Hany, T., Samarin, A., Biaggi, C., Rusterholz, C., Dirnhofer, S., Zucca, E., & Martinelli, G. (2015). Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Journal of clinical oncology : official journal of the American Society of Clinical Oncology33(23), 2523–2529. https://doi.org/10.1200/JCO.2014.58.9846

  • Hüttmann, A., Müller, S., Jöckel, K. H., & Dührsen, U. (2010). Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology28(27), e488–e491. https://doi.org/10.1200/JCO.2010.29.5428

  • Dührsen, U., Hüttmann, A., Jöckel, K. H., & Müller, S. (2009). Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas–the PETAL trial. Leukemia & lymphoma50(11), 1757–1760. https://doi.org/10.3109/10428190903308031

Theses

  • Eertink, J. J. (2023). New perspectives on the role of PET imaging in diffuse large B-cell lymphoma. [PhD-Thesis – Research and graduation internal, Vrije Universiteit Amsterdam].

  • Burggraaff, C. N. (2022). 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation. [PhD-Thesis – Research and graduation internal, Vrije Universiteit Amsterdam].